PhenID ::: StudyID ::: DATASETID ::: DATASET NAME ::: PHEN NAME ::: PHEN DESCRIPTION ::: PHEN TYPE ::: PHEN UNIT ::: PHEN MIN ::: PHEN MAX ::: NORMED ::: THEME ::: THEME PCN ::: THEME CUI ::: THEME STT ::: TOPIC PCN ::: TOPIC CUI ::: TOPIC SST ::: SOI PCN ::: SOI CUI ::: SOI SST
phv00076256.v2 ::: phs000206.v3.p2 ::: pht000895.v3 ::: CGEMS_PANSCAN_Data ::: case_control ::: Case or control? ::: string ::: NONE ::: NONE ::: NONE ::: case or control ::: NULL ::: NULL ::: NULL ::: NULL ::: control aspects ::: C0243148 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00089657.v2 ::: phs000206.v3.p2 ::: pht000895.v3 ::: CGEMS_PANSCAN_Data ::: study_design ::: Cohort study or case-control study ::: string ::: NONE ::: NONE ::: NONE ::: cohort study or case control study ::: NULL ::: NULL ::: NULL ::: NULL ::: case-control studies ::: C0007328 ::: resa ::: study subject ::: C0681850 ::: grup
phv00076258.v2 ::: phs000206.v3.p2 ::: pht000895.v3 ::: CGEMS_PANSCAN_Data ::: sex ::: Gender of the participant ::: string ::: NONE ::: NONE ::: NONE ::: gender of the participant ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: gender:type:point in time:^patient:nominal ::: C0804628 ::: clna ::: participant ::: C0679646 ::: popg
phv00076254.v2 ::: phs000206.v3.p2 ::: pht000895.v3 ::: CGEMS_PANSCAN_Data ::: SUBJID ::: De-identified subject's ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject s id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076257.v2 ::: phs000206.v3.p2 ::: pht000895.v3 ::: CGEMS_PANSCAN_Data ::: age ::: Age at enrollment in 10 year interval ::: string ::: Years old ::: NONE ::: NONE ::: age at enrollment in 10 year interval ::: Age ::: age ::: C0001779 ::: orga ::: enrollment ::: C1516879 ::: hlca ::: study subject ::: C0681850 ::: grup
phv00076259.v2 ::: phs000206.v3.p2 ::: pht000896.v2 ::: CGEMS_PANSCAN_Subject ::: SUBJID ::: De-identified subject's ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject s id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076260.v2 ::: phs000206.v3.p2 ::: pht000896.v2 ::: CGEMS_PANSCAN_Subject ::: CONSENT ::: Consent group as determined by DAC ::: string ::: NONE ::: NONE ::: NONE ::: consent group as determined by dac ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076261.v2 ::: phs000206.v3.p2 ::: pht000896.v2 ::: CGEMS_PANSCAN_Subject ::: Affection Status ::: Case or control status of the subject ::: string ::: NONE ::: NONE ::: NONE ::: case or control status of the subject ::: NULL ::: NULL ::: NULL ::: NULL ::: status;control aspects ::: C0449438;C0243148 ::: qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076263.v2 ::: phs000206.v3.p2 ::: pht000897.v2 ::: CGEMS_PANSCAN_Sample ::: SAMPID ::: De-identified sample's ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified sample s id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076262.v2 ::: phs000206.v3.p2 ::: pht000897.v2 ::: CGEMS_PANSCAN_Sample ::: SUBJID ::: De-identified subject's ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject s id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076172.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: NRAS ::: Does participant have a somatic mutation in NRAS (Entrez GeneID: 4893)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in nras  entrez geneid  4893 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076179.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: SPI1 ::: Does participant have a somatic mutation in SPI1 (Entrez GeneID: 6688)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in spi1  entrez geneid  6688 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076152.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Treatment Protocol ::: Treatment protocol given to patient ::: encoded value ::: NONE ::: NONE ::: NONE ::: treatment protocol given to patient ::: NULL ::: NULL ::: NULL ::: NULL ::: treatment protocols ::: C0040808 ::: topp ::: patients ::: C0030705 ::: podg
phv00076154.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Patient expired ::: Has patient expired? ::: string ::: NONE ::: NONE ::: NONE ::: has patient expired ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: patients ::: C0030705 ::: podg
phv00076149.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Age at entry ::: Age at diagnosis ::: integer ::: years ::: 18 ::: 81 ::: age at diagnosis ::: Age ::: age ::: C0001779 ::: orga ::: diagnosis;diagnosis aspect;diagnosis study ::: C0011900;C1704338;C1704656 ::: fndg;qlco;resa ::: study subject ::: C0681850 ::: grup
phv00076163.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone 5 ::: Cytogenetic abnormality found in clone 5 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 5  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076164.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (clone 5) ::: # of abnormal cells in clone 5/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 5 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076165.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: months of OS (as of 10/28/08) ::: # of months of Overall Survival ::: decimal ::: months ::: 0.2 ::: 77.2 ::: number  of months of overall survival ::: NULL ::: NULL ::: NULL ::: NULL ::: overall ::: C1561607 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00076160.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (clone 3) ::: # of abnormal cells in clone 3/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 3 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076158.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (Clone 2) ::: # of abnormal cells in clone 2/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 2 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076144.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: case_control ::: Case or control? ::: encoded value ::: NONE ::: NONE ::: NONE ::: case or control ::: NULL ::: NULL ::: NULL ::: NULL ::: control aspects ::: C0243148 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00076175.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: CEBPA ::: Does participant have a somatic mutation in CEBPA (Entrez GeneID: 1050)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in cebpa  entrez geneid  1050 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076168.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: ETV6 ::: Does participant have a somatic mutation in ETV6 (Entrez GeneID: 2120)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in etv6  entrez geneid  2120 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076150.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Race ::: Subject's Race ::: string ::: NONE ::: NONE ::: NONE ::: subject s race ::: Race ::: racial group ::: C0034510 ::: popg :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076171.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: c-Kit ::: Does participant have a somatic mutation in c-KIT (Entrez GeneID: 3815)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in ckit  entrez geneid  3815 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076155.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone 1 ::: Cytogenetic abnormality found in clone 1 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 1  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076148.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: PB WBC @ diagnosis ::: What was the peripheral blood White Blood Cell Count at diagnosis? ::: decimal ::: 10^3/ul ::: 0.4 ::: 297.4 ::: what was the peripheral blood white blood cell count at diagnosis ::: NULL ::: NULL ::: NULL ::: NULL ::: white blood cell count procedure;diagnosis;diagnosis aspect;diagnosis study ::: C0023508;C0011900;C1704338;C1704656 ::: lbpr;fndg;qlco;resa ::: study subject ::: C0681850 ::: grup
phv00076146.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Sex ::: Gender of participant ::: encoded value ::: NONE ::: NONE ::: NONE ::: gender of participant ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: gender:type:point in time:^patient:nominal ::: C0804628 ::: clna ::: participant ::: C0679646 ::: popg
phv00076178.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: RUNX1 ::: Does participant have a somatic mutation in RUNX1 (Entrez GeneID: 861)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in runx1  entrez geneid  861 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076174.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: NPM1 ::: Does participant have a somatic mutation in NPM1 (Entrez GeneID: 4869)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in npm1  entrez geneid  4869 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076161.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone 4 ::: Cytogenetic abnormality found in clone 4 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 4  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076145.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: FAB ::: French-American-British (FAB) classification category for bone marrow biopsy and aspirate ::: integer, string ::: NONE ::: NONE ::: NONE ::: french american british  fab  classification category for bone marrow biopsy and aspirate ::: Race ::: french race;american;british ::: C1556084;C0596070;C0596227 ::: popg;popg;popg ::: bone marrow biopsy ::: C0005954 ::: diap ::: study subject ::: C0681850 ::: grup
phv00076143.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: SUBJID ::: Deidentified Subject's ID/Unique Patient Name (UPN) ::: integer ::: NONE ::: NONE ::: NONE ::: deidentified subject s id unique patient name  upn ::: NULL ::: NULL ::: NULL ::: NULL ::: unique;patient name ::: C1710548;C1299487 ::: qlco;fndg ::: study subject ::: C0681850 ::: grup
phv00076169.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: FLT3 - ITD ::: Does participant have a somatic internal tandem duplication (ITD) in FLT3 (Entrez GeneID: 2322)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic internal tandem duplication  itd  in flt3  entrez geneid  2322 ::: NULL ::: NULL ::: NULL ::: NULL ::: tandem;soma ::: C0075804;C0702216 ::: orch,phsu;orch,phsu ::: participant ::: C0679646 ::: popg
phv00076170.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: FLT3 - D835 ::: Does participant have a somatic D835 mutation in FLT3 (Entrez GeneID: 2322)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic d835  mutation in flt3  entrez geneid  2322 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076177.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: p53 ::: Does participant have a somatic mutation in p53 (Entrez GeneID: 7157)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in p53   entrez geneid  7157 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076176.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: PTPN11 ::: Does participant have a somatic mutation in PTPN11 (Entrez GeneID: 5781)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in ptpn11   entrez geneid  5781 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076156.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (clone 1) ::: # of abnormal cells in clone 1/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 1 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076173.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: KRAS ::: Does participant have a somatic mutation in KRAS (Entrez GeneID: 3845)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in kras  entrez geneid  3845 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076153.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Transplant Type ::: Type(s) of transplant patient received, if any ::: encoded value ::: NONE ::: NONE ::: NONE ::: type s  of transplant patient received, if any ::: NULL ::: NULL ::: NULL ::: NULL ::: type - attribute;transplantation;receive ::: C0332307;C0040732;C1514756 ::: qlco;topp;qlco ::: patients ::: C0030705 ::: podg
phv00076166.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: months of EFS (as of 10/28/08) ::: # of months of Event Free Survival ::: decimal ::: months ::: 0.2 ::: 65.4 ::: number  of months of event free survival ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076147.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: %BM Blast @ diagnosis ::: What percentage of myeloblasts were present in the bone marrow at the time of diagnosis? ::: integer ::: % ::: 30 ::: 100 ::: what percentage of myeloblasts were present in the bone marrow at the time of diagnosis ::: NULL ::: NULL ::: NULL ::: NULL ::: myeloblast count procedure;diagnosis;diagnosis aspect;diagnosis study ::: C0580952;C0011900;C1704338;C1704656 ::: lbpr;fndg;qlco;resa ::: study subject ::: C0681850 ::: grup
phv00076162.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (clone 4) ::: # of abnormal cells in clone 4/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 4 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076159.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone3 ::: Cytogenetic abnormality found in clone 3 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 3  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076151.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: %PB Blast ::: What percentage of blasts were present in the peripheral blood at diagnosis? ::: integer, string ::: % ::: 0 ::: 97 ::: what percentage of blasts were present in the peripheral blood at diagnosis ::: NULL ::: NULL ::: NULL ::: NULL ::: blast count procedure;diagnosis;diagnosis aspect;diagnosis study ::: C0523113;C0011900;C1704338;C1704656 ::: lbpr;fndg;qlco;resa ::: study subject ::: C0681850 ::: grup
phv00076157.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone 2 ::: Cytogenetic abnormality found in clone 2 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 2  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076167.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: NUP98 fusion ::: Does participant have a NUP98 fusion (Entrez GeneID: 4928)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a nup98  fusion  entrez geneid  4928 ::: NULL ::: NULL ::: NULL ::: NULL ::: fusion procedure ::: C1293131 ::: topp ::: participant ::: C0679646 ::: popg
phv00076188.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: TISSUE ::: Tissue of origin from which sample was made ::: string ::: NONE ::: NONE ::: NONE ::: tissue of origin from which sample was made ::: NULL ::: NULL ::: NULL ::: NULL ::: national origin ::: C0079946 ::: clna ::: study subject ::: C0681850 ::: grup
phv00076189.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: SOURCE_SAMPID ::: Sample ID used in the Source Repository ::: string ::: NONE ::: NONE ::: NONE ::: sample id used in the source repository ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;source ::: C1273517;C0449416 ::: fndg;fndg ::: study subject ::: C0681850 ::: grup
phv00076186.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: SAMPID ::: CEL file and txt file chip ID ::: string ::: NONE ::: NONE ::: NONE ::: cel file and txt file chip id ::: NULL ::: NULL ::: NULL ::: NULL ::: chronic eosinophilic leukemia;taxotere ::: C0346421;C0699967 ::: neop;orch,phsu ::: study subject ::: C0681850 ::: grup
phv00076187.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: SAMP_SOURCE ::: Source repository where samples originate ::: string ::: NONE ::: NONE ::: NONE ::: source repository where samples originate ::: NULL ::: NULL ::: NULL ::: NULL ::: source ::: C0449416 ::: fndg ::: study subject ::: C0681850 ::: grup
phv00076185.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: SUBJID ::: Deidentified Subject's ID/Unique Patient Name (UPN) ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject s id unique patient name  upn ::: NULL ::: NULL ::: NULL ::: NULL ::: unique;patient name ::: C1710548;C1299487 ::: qlco;fndg ::: study subject ::: C0681850 ::: grup
phv00076183.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: SOURCE_SUBJID ::: Subject ID used in the Source Repository ::: string ::: NONE ::: NONE ::: NONE ::: subject id used in the source repository ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;source ::: C1273517;C0449416 ::: fndg;fndg ::: study subject ::: C0681850 ::: grup
phv00076180.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: SUBJID ::: Deidentified Subject's ID/Unique Patient Name (UPN) ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject s id unique patient name  upn ::: NULL ::: NULL ::: NULL ::: NULL ::: unique;patient name ::: C1710548;C1299487 ::: qlco;fndg ::: study subject ::: C0681850 ::: grup
phv00076181.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: CONSENT ::: Consent group as determined by DAC ::: encoded value ::: NONE ::: NONE ::: NONE ::: consent group as determined by dac ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076184.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: AFFECTION_STATUS ::: Affection Status ::: encoded value ::: NONE ::: NONE ::: NONE ::: affection status ::: NULL ::: NULL ::: NULL ::: NULL ::: affection;status ::: C0871641;C0449438 ::: menp;qlco ::: study subject ::: C0681850 ::: grup
phv00076182.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: SUBJ_SOURCE ::: Source repository where subjects originate ::: string ::: NONE ::: NONE ::: NONE ::: source repository where subjects originate ::: NULL ::: NULL ::: NULL ::: NULL ::: source ::: C0449416 ::: fndg ::: study subject ::: C0681850 ::: grup
phv00076183.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: SOURCE_SUBJID ::: Subject ID used in the Source Repository ::: string ::: NONE ::: NONE ::: NONE ::: subject id used in the source repository ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;source ::: C1273517;C0449416 ::: fndg;fndg ::: study subject ::: C0681850 ::: grup
phv00076180.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: SUBJID ::: Deidentified Subject's ID/Unique Patient Name (UPN) ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject s id unique patient name  upn ::: NULL ::: NULL ::: NULL ::: NULL ::: unique;patient name ::: C1710548;C1299487 ::: qlco;fndg ::: study subject ::: C0681850 ::: grup
phv00076181.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: CONSENT ::: Consent group as determined by DAC ::: encoded value ::: NONE ::: NONE ::: NONE ::: consent group as determined by dac ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076184.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: AFFECTION_STATUS ::: Affection Status ::: encoded value ::: NONE ::: NONE ::: NONE ::: affection status ::: NULL ::: NULL ::: NULL ::: NULL ::: affection;status ::: C0871641;C0449438 ::: menp;qlco ::: study subject ::: C0681850 ::: grup
phv00076182.v1 ::: phs000201.v1.p1 ::: pht000886.v1 ::: AML_Subject ::: SUBJ_SOURCE ::: Source repository where subjects originate ::: string ::: NONE ::: NONE ::: NONE ::: source repository where subjects originate ::: NULL ::: NULL ::: NULL ::: NULL ::: source ::: C0449416 ::: fndg ::: study subject ::: C0681850 ::: grup
phv00076172.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: NRAS ::: Does participant have a somatic mutation in NRAS (Entrez GeneID: 4893)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in nras  entrez geneid  4893 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076179.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: SPI1 ::: Does participant have a somatic mutation in SPI1 (Entrez GeneID: 6688)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in spi1  entrez geneid  6688 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076152.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Treatment Protocol ::: Treatment protocol given to patient ::: encoded value ::: NONE ::: NONE ::: NONE ::: treatment protocol given to patient ::: NULL ::: NULL ::: NULL ::: NULL ::: treatment protocols ::: C0040808 ::: topp ::: patients ::: C0030705 ::: podg
phv00076154.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Patient expired ::: Has patient expired? ::: string ::: NONE ::: NONE ::: NONE ::: has patient expired ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: patients ::: C0030705 ::: podg
phv00076149.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Age at entry ::: Age at diagnosis ::: integer ::: years ::: 18 ::: 81 ::: age at diagnosis ::: Age ::: age ::: C0001779 ::: orga ::: diagnosis;diagnosis aspect;diagnosis study ::: C0011900;C1704338;C1704656 ::: fndg;qlco;resa ::: study subject ::: C0681850 ::: grup
phv00076163.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone 5 ::: Cytogenetic abnormality found in clone 5 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 5  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076164.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (clone 5) ::: # of abnormal cells in clone 5/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 5 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076165.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: months of OS (as of 10/28/08) ::: # of months of Overall Survival ::: decimal ::: months ::: 0.2 ::: 77.2 ::: number  of months of overall survival ::: NULL ::: NULL ::: NULL ::: NULL ::: overall ::: C1561607 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00076160.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (clone 3) ::: # of abnormal cells in clone 3/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 3 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076158.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (Clone 2) ::: # of abnormal cells in clone 2/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 2 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076144.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: case_control ::: Case or control? ::: encoded value ::: NONE ::: NONE ::: NONE ::: case or control ::: NULL ::: NULL ::: NULL ::: NULL ::: control aspects ::: C0243148 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00076175.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: CEBPA ::: Does participant have a somatic mutation in CEBPA (Entrez GeneID: 1050)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in cebpa  entrez geneid  1050 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076168.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: ETV6 ::: Does participant have a somatic mutation in ETV6 (Entrez GeneID: 2120)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in etv6  entrez geneid  2120 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076150.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Race ::: Subject's Race ::: string ::: NONE ::: NONE ::: NONE ::: subject s race ::: Race ::: racial group ::: C0034510 ::: popg :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076171.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: c-Kit ::: Does participant have a somatic mutation in c-KIT (Entrez GeneID: 3815)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in ckit  entrez geneid  3815 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076155.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone 1 ::: Cytogenetic abnormality found in clone 1 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 1  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076148.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: PB WBC @ diagnosis ::: What was the peripheral blood White Blood Cell Count at diagnosis? ::: decimal ::: 10^3/ul ::: 0.4 ::: 297.4 ::: what was the peripheral blood white blood cell count at diagnosis ::: NULL ::: NULL ::: NULL ::: NULL ::: white blood cell count procedure;diagnosis;diagnosis aspect;diagnosis study ::: C0023508;C0011900;C1704338;C1704656 ::: lbpr;fndg;qlco;resa ::: study subject ::: C0681850 ::: grup
phv00076146.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Sex ::: Gender of participant ::: encoded value ::: NONE ::: NONE ::: NONE ::: gender of participant ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: gender:type:point in time:^patient:nominal ::: C0804628 ::: clna ::: participant ::: C0679646 ::: popg
phv00076178.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: RUNX1 ::: Does participant have a somatic mutation in RUNX1 (Entrez GeneID: 861)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in runx1  entrez geneid  861 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076174.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: NPM1 ::: Does participant have a somatic mutation in NPM1 (Entrez GeneID: 4869)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in npm1  entrez geneid  4869 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076161.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone 4 ::: Cytogenetic abnormality found in clone 4 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 4  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076145.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: FAB ::: French-American-British (FAB) classification category for bone marrow biopsy and aspirate ::: integer, string ::: NONE ::: NONE ::: NONE ::: french american british  fab  classification category for bone marrow biopsy and aspirate ::: Race ::: french race;american;british ::: C1556084;C0596070;C0596227 ::: popg;popg;popg ::: bone marrow biopsy ::: C0005954 ::: diap ::: study subject ::: C0681850 ::: grup
phv00076143.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: SUBJID ::: Deidentified Subject's ID/Unique Patient Name (UPN) ::: integer ::: NONE ::: NONE ::: NONE ::: deidentified subject s id unique patient name  upn ::: NULL ::: NULL ::: NULL ::: NULL ::: unique;patient name ::: C1710548;C1299487 ::: qlco;fndg ::: study subject ::: C0681850 ::: grup
phv00076169.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: FLT3 - ITD ::: Does participant have a somatic internal tandem duplication (ITD) in FLT3 (Entrez GeneID: 2322)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic internal tandem duplication  itd  in flt3  entrez geneid  2322 ::: NULL ::: NULL ::: NULL ::: NULL ::: tandem;soma ::: C0075804;C0702216 ::: orch,phsu;orch,phsu ::: participant ::: C0679646 ::: popg
phv00076170.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: FLT3 - D835 ::: Does participant have a somatic D835 mutation in FLT3 (Entrez GeneID: 2322)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic d835  mutation in flt3  entrez geneid  2322 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076177.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: p53 ::: Does participant have a somatic mutation in p53 (Entrez GeneID: 7157)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in p53   entrez geneid  7157 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076176.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: PTPN11 ::: Does participant have a somatic mutation in PTPN11 (Entrez GeneID: 5781)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in ptpn11   entrez geneid  5781 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076156.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (clone 1) ::: # of abnormal cells in clone 1/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 1 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076173.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: KRAS ::: Does participant have a somatic mutation in KRAS (Entrez GeneID: 3845)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a somatic mutation in kras  entrez geneid  3845 ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00076153.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Transplant Type ::: Type(s) of transplant patient received, if any ::: encoded value ::: NONE ::: NONE ::: NONE ::: type s  of transplant patient received, if any ::: NULL ::: NULL ::: NULL ::: NULL ::: type - attribute;transplantation;receive ::: C0332307;C0040732;C1514756 ::: qlco;topp;qlco ::: patients ::: C0030705 ::: podg
phv00076166.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: months of EFS (as of 10/28/08) ::: # of months of Event Free Survival ::: decimal ::: months ::: 0.2 ::: 65.4 ::: number  of months of event free survival ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00076147.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: %BM Blast @ diagnosis ::: What percentage of myeloblasts were present in the bone marrow at the time of diagnosis? ::: integer ::: % ::: 30 ::: 100 ::: what percentage of myeloblasts were present in the bone marrow at the time of diagnosis ::: NULL ::: NULL ::: NULL ::: NULL ::: myeloblast count procedure;diagnosis;diagnosis aspect;diagnosis study ::: C0580952;C0011900;C1704338;C1704656 ::: lbpr;fndg;qlco;resa ::: study subject ::: C0681850 ::: grup
phv00076162.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Abnormal/Total Cells (clone 4) ::: # of abnormal cells in clone 4/total cells evaluated  (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: number  of abnormal cells in clone 4 total cells evaluated  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: total;not applicable;applicable ::: C0439810;C1272460;C1706839 ::: qlco;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076159.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone3 ::: Cytogenetic abnormality found in clone 3 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 3  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076151.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: %PB Blast ::: What percentage of blasts were present in the peripheral blood at diagnosis? ::: integer, string ::: % ::: 0 ::: 97 ::: what percentage of blasts were present in the peripheral blood at diagnosis ::: NULL ::: NULL ::: NULL ::: NULL ::: blast count procedure;diagnosis;diagnosis aspect;diagnosis study ::: C0523113;C0011900;C1704338;C1704656 ::: lbpr;fndg;qlco;resa ::: study subject ::: C0681850 ::: grup
phv00076157.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: Cytogenetics Clone 2 ::: Cytogenetic abnormality found in clone 2 (if applicable) ::: string ::: NONE ::: NONE ::: NONE ::: cytogenetic abnormality found in clone 2  if applicable ::: NULL ::: NULL ::: NULL ::: NULL ::: signs and symptoms;finding;experimental finding;not applicable;applicable ::: C0037088;C0243095;C2825141;C1272460;C1706839 ::: sosy;fndg;fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00076167.v1 ::: phs000201.v1.p1 ::: pht000885.v1 ::: AML_Data ::: NUP98 fusion ::: Does participant have a NUP98 fusion (Entrez GeneID: 4928)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: does participant have a nup98  fusion  entrez geneid  4928 ::: NULL ::: NULL ::: NULL ::: NULL ::: fusion procedure ::: C1293131 ::: topp ::: participant ::: C0679646 ::: popg
phv00076188.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: TISSUE ::: Tissue of origin from which sample was made ::: string ::: NONE ::: NONE ::: NONE ::: tissue of origin from which sample was made ::: NULL ::: NULL ::: NULL ::: NULL ::: national origin ::: C0079946 ::: clna ::: study subject ::: C0681850 ::: grup
phv00076189.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: SOURCE_SAMPID ::: Sample ID used in the Source Repository ::: string ::: NONE ::: NONE ::: NONE ::: sample id used in the source repository ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;source ::: C1273517;C0449416 ::: fndg;fndg ::: study subject ::: C0681850 ::: grup
phv00076186.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: SAMPID ::: CEL file and txt file chip ID ::: string ::: NONE ::: NONE ::: NONE ::: cel file and txt file chip id ::: NULL ::: NULL ::: NULL ::: NULL ::: chronic eosinophilic leukemia;taxotere ::: C0346421;C0699967 ::: neop;orch,phsu ::: study subject ::: C0681850 ::: grup
phv00076187.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: SAMP_SOURCE ::: Source repository where samples originate ::: string ::: NONE ::: NONE ::: NONE ::: source repository where samples originate ::: NULL ::: NULL ::: NULL ::: NULL ::: source ::: C0449416 ::: fndg ::: study subject ::: C0681850 ::: grup
phv00076185.v1 ::: phs000201.v1.p1 ::: pht000887.v1 ::: AML_Sample ::: SUBJID ::: Deidentified Subject's ID/Unique Patient Name (UPN) ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject s id unique patient name  upn ::: NULL ::: NULL ::: NULL ::: NULL ::: unique;patient name ::: C1710548;C1299487 ::: qlco;fndg ::: study subject ::: C0681850 ::: grup
phv00167551.v1 ::: phs000223.v1.p1 ::: pht002619.v1 ::: ARIC_PAGE_pilot_Subject ::: SOURCE_SUBJID ::: Subject ID used in the Source Repository [Geneva ID] ::: string ::: NONE ::: NONE ::: NONE ::: subject id used in the source repository  geneva id ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;source ::: C1273517;C0449416 ::: fndg;fndg ::: study subject ::: C0681850 ::: grup
phv00167549.v1 ::: phs000223.v1.p1 ::: pht002619.v1 ::: ARIC_PAGE_pilot_Subject ::: Consent ::: Consent group as determined by DAC ::: encoded value ::: NONE ::: NONE ::: NONE ::: consent group as determined by dac ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167548.v1 ::: phs000223.v1.p1 ::: pht002619.v1 ::: ARIC_PAGE_pilot_Subject ::: SUBJID ::: Subject ID ::: string ::: NONE ::: NONE ::: NONE ::: subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167550.v1 ::: phs000223.v1.p1 ::: pht002619.v1 ::: ARIC_PAGE_pilot_Subject ::: SUBJ_SOURCE ::: Source repository where subjects originate [Geneva] ::: string ::: NONE ::: NONE ::: NONE ::: source repository where subjects originate  geneva ::: NULL ::: NULL ::: NULL ::: NULL ::: source ::: C0449416 ::: fndg ::: study subject ::: C0681850 ::: grup
phv00167552.v1 ::: phs000223.v1.p1 ::: pht002620.v1 ::: PAGE_ARIC_Sample ::: IID.GenomeStudio ::: Sample ID ::: string ::: NONE ::: NONE ::: NONE ::: sample id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167553.v1 ::: phs000223.v1.p1 ::: pht002620.v1 ::: PAGE_ARIC_Sample ::: IID.Genotyping ::: Subject ID ::: string ::: NONE ::: NONE ::: NONE ::: subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167554.v1 ::: phs000223.v1.p1 ::: pht002620.v1 ::: PAGE_ARIC_Sample ::: SAMPLE_USE ::: Sample use ::: NONE ::: NONE ::: NONE ::: NONE ::: sample use ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167555.v1 ::: phs000223.v1.p1 ::: pht002621.v1 ::: ARIC_PAGE_pilot_SubjectGenders ::: SUBJID ::: Subject ID ::: string ::: NONE ::: NONE ::: NONE ::: subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167556.v1 ::: phs000223.v1.p1 ::: pht002621.v1 ::: ARIC_PAGE_pilot_SubjectGenders ::: SEX ::: Sample ID ::: string ::: NONE ::: NONE ::: NONE ::: sample id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167982.v1 ::: phs000477.v1.p1 ::: pht002687.v1 ::: Familial_Renal_Disorders_Subject_Phenotypes ::: disease ::: Primary disease of participant ::: string ::: NONE ::: NONE ::: NONE ::: primary disease of participant ::: NULL ::: NULL ::: NULL ::: NULL ::: primary disease ::: C0277554 ::: dsyn ::: participant ::: C0679646 ::: popg
phv00167981.v1 ::: phs000477.v1.p1 ::: pht002687.v1 ::: Familial_Renal_Disorders_Subject_Phenotypes ::: sex ::: Gender of participant ::: encoded value ::: NONE ::: NONE ::: NONE ::: gender of participant ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: gender:type:point in time:^patient:nominal ::: C0804628 ::: clna ::: participant ::: C0679646 ::: popg
phv00167980.v1 ::: phs000477.v1.p1 ::: pht002687.v1 ::: Familial_Renal_Disorders_Subject_Phenotypes ::: SUBJID ::: De-identified Subject ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167978.v1 ::: phs000477.v1.p1 ::: pht002686.v1 ::: Familial_Renal_Disorders_Sample ::: SAMPID ::: Sample ID ::: string ::: NONE ::: NONE ::: NONE ::: sample id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167979.v1 ::: phs000477.v1.p1 ::: pht002686.v1 ::: Familial_Renal_Disorders_Sample ::: SAMPLE_USE ::: Type of data submitted ::: string ::: NONE ::: NONE ::: NONE ::: type of data submitted ::: NULL ::: NULL ::: NULL ::: NULL ::: type - attribute ::: C0332307 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00167977.v1 ::: phs000477.v1.p1 ::: pht002686.v1 ::: Familial_Renal_Disorders_Sample ::: SUBJID ::: Subject ID ::: string ::: NONE ::: NONE ::: NONE ::: subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167976.v1 ::: phs000477.v1.p1 ::: pht002685.v1 ::: Familial_Renal_Disorders_Subject ::: CONSENT ::: Consent status ::: encoded value ::: NONE ::: NONE ::: NONE ::: consent status ::: NULL ::: NULL ::: NULL ::: NULL ::: consent status ::: C0586888 ::: fndg ::: study subject ::: C0681850 ::: grup
phv00167974.v1 ::: phs000477.v1.p1 ::: pht002685.v1 ::: Familial_Renal_Disorders_Subject ::: SUBJID ::: Subject ID ::: string ::: NONE ::: NONE ::: NONE ::: subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00167975.v1 ::: phs000477.v1.p1 ::: pht002685.v1 ::: Familial_Renal_Disorders_Subject ::: AFFECTION_STATUS ::: Case control status of the subject ::: encoded value ::: NONE ::: NONE ::: NONE ::: case control status of the subject ::: NULL ::: NULL ::: NULL ::: NULL ::: case control;status ::: C0872128;C0449438 ::: hlca;qlco ::: study subject ::: C0681850 ::: grup
phv00167984.v1 ::: phs000477.v1.p1 ::: pht002688.v1 ::: Familial_Renal_Disorders_Sample_Attributes ::: ANALYTE_TYPE ::: Analyte Type ::: string ::: NONE ::: NONE ::: NONE ::: analyte type ::: NULL ::: NULL ::: NULL ::: NULL ::: type - attribute ::: C0332307 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00167983.v1 ::: phs000477.v1.p1 ::: pht002688.v1 ::: Familial_Renal_Disorders_Sample_Attributes ::: SAMPID ::: De-identified Sample ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified sample id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00158801.v1 ::: phs000237.v1.p1 ::: pht002159.v1 ::: NU_VU_T2D_Subject ::: SUBJID ::: Subject ID ::: integer ::: NONE ::: NONE ::: NONE ::: subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00158802.v1 ::: phs000237.v1.p1 ::: pht002159.v1 ::: NU_VU_T2D_Subject ::: CONSENT ::: Consent group as determined by DAC ::: integer, encoded value ::: NONE ::: NONE ::: NONE ::: consent group as determined by dac ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00158803.v1 ::: phs000237.v1.p1 ::: pht002159.v1 ::: NU_VU_T2D_Subject ::: SUBJ_SOURCE ::: Source repository where subjects originate ::: string ::: NONE ::: NONE ::: NONE ::: source repository where subjects originate ::: NULL ::: NULL ::: NULL ::: NULL ::: source ::: C0449416 ::: fndg ::: study subject ::: C0681850 ::: grup
phv00158804.v1 ::: phs000237.v1.p1 ::: pht002159.v1 ::: NU_VU_T2D_Subject ::: SOURCE_SUBJID ::: Subject ID used in the Source Repository ::: integer ::: NONE ::: NONE ::: NONE ::: subject id used in the source repository ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;source ::: C1273517;C0449416 ::: fndg;fndg ::: study subject ::: C0681850 ::: grup
phv00158805.v1 ::: phs000237.v1.p1 ::: pht002159.v1 ::: NU_VU_T2D_Subject ::: AFFECTION_STATUS ::: Affection Status ::: integer, encoded value ::: NONE ::: NONE ::: NONE ::: affection status ::: NULL ::: NULL ::: NULL ::: NULL ::: affection;status ::: C0871641;C0449438 ::: menp;qlco ::: study subject ::: C0681850 ::: grup
phv00158838.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Age_last_known_type2_diabetes_drug_prescribed ::: Age when last known type 2 diabetes drug (in the following classes: Sulfonylureas, Meglitinides, Biguanides, Thiazoldinediones, Alpha-glucosidase inhibitors, DPPIV inhibitor (sitagliptin), or the injectable exenatide) prescribed ::: integer, encoded value ::: Years ::: 17 ::: 90 ::: age when last known type 2 diabetes drug  in the following classes  sulfonylureas, meglitinides, biguanides, thiazoldinediones, alpha glucosidase inhibitors, dppiv inhibitor  sitagliptin , or the injectable exenatide  prescribed ::: Age ::: age ::: C0001779 ::: orga ::: known;diabetes mellitus, non-insulin-dependent;pharmaceutical preparations;pharmacologic substance;sulfonylurea compounds;meglitinide;meglitinides;biguanides;alpha-glucoside inhibitor;inhibitor;sitagliptin;exenatide;injection procedure;prescribed ::: C0205309;C0011860;C0013227;C1254351;C0038766;C0065880;C1579432;C0005382;C1299007;C1999216;C1565750;C0167117;C1533685;C0278329 ::: qlco;dsyn;phsu;phsu;orch,phsu;orch,phsu;phsu;orch,phsu;phsu;qlco;orch,phsu;aapp,phsu;topp;hlca ::: study subject ::: C0681850 ::: grup
phv00158825.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: AGE_TYPE_2_DIABETES_ONSET ::: Patient's age at the earliest indication of T2DM ::: integer, encoded value ::: Years ::: 11 ::: 90 ::: patient s age at the earliest indication of t2 dm ::: Age ::: age ::: C0001779 ::: orga :::  :::  :::  ::: patients ::: C0030705 ::: podg
phv00158835.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Age_first_type1_diabetes_drug_prescribed ::: Age when first known type 1 diabetes drug (insulin, Symlin, or any insulin supply) prescribed ::: integer, encoded value ::: Years ::: 10 ::: 90 ::: age when first known type 1 diabetes drug  insulin, symlin, or any insulin supply  prescribed ::: Age ::: age ::: C0001779 ::: orga ::: known;diabetes mellitus, insulin-dependent;pharmaceutical preparations;insulin;recombinant insulin;pharmacologic substance;firstly;symlin;prescribed ::: C0205309;C0011854;C0013227;C0021641;C1533581;C1254351;C1279901;C1174780;C0278329 ::: qlco;dsyn;phsu;aapp,horm,phsu;aapp,horm,phsu;phsu;qlco;aapp,horm,phsu;hlca ::: study subject ::: C0681850 ::: grup
phv00158834.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Any_diabetes_drug_prescribed_indicator ::: Were any diabetes drugs (Sulfonylureas, Meglitinides, Biguanides, Thiazoldinediones, Alpha-glucosidase inhibitors, DPPIV inhibitor (sitagliptin), exenatide, insulin, Symlin, or any diabetic supply including insulin needles and glucose monitors) prescribed ::: encoded value ::: NONE ::: NONE ::: NONE ::: were any diabetes drugs  sulfonylureas, meglitinides, biguanides, thiazoldinediones, alpha glucosidase inhibitors, dppiv inhibitor  sitagliptin , exenatide, insulin, symlin, or any diabetic supply including insulin needles and glucose monitors  prescribed ::: NULL ::: NULL ::: NULL ::: NULL ::: diabetes;pharmaceutical preparations;sulfonylurea compounds;diabetes mellitus;meglitinide;meglitinides;biguanides;alpha-glucoside inhibitor;inhibitor;sitagliptin;exenatide;insulin;recombinant insulin;symlin;diabetic;prescribed ::: C0011847;C0013227;C0038766;C0011849;C0065880;C1579432;C0005382;C1299007;C1999216;C1565750;C0167117;C0021641;C1533581;C1174780;C0241863;C0278329 ::: dsyn;phsu;orch,phsu;dsyn;orch,phsu;phsu;orch,phsu;phsu;qlco;orch,phsu;aapp,phsu;aapp,horm,phsu;aapp,horm,phsu;aapp,horm,phsu;fndg;hlca ::: study subject ::: C0681850 ::: grup
phv00158826.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: DIABETES_FAMILY_HISTORY ::: Family History of Diabetes ::: encoded value ::: NONE ::: NONE ::: NONE ::: family history of diabetes ::: NULL ::: NULL ::: NULL ::: NULL ::: family history of;diabetes;diabetes mellitus ::: C0241889;C0011847;C0011849 ::: fndg;dsyn;dsyn ::: family ::: C0015576 ::: fndg
phv00158817.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: ENROLLMENT_AGE ::: Age at Enrollment in DNA biorepository ::: integer, encoded value ::: Years ::: 18 ::: 90 ::: age at enrollment in dna biorepository ::: Age ::: age ::: C0001779 ::: orga ::: enrollment ::: C1516879 ::: hlca ::: study subject ::: C0681850 ::: grup
phv00158832.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Age_last_known_type1_diabetes_diagnosis_code ::: Age when last known type 1 diabetes diagnosis code was given (ICD-9 codes 250.x1 or 250.x3, where x is any digit) ::: integer, encoded value ::: Years ::: 19 ::: 90 ::: age when last known type 1 diabetes diagnosis code was given  icd 9 codes 250 x1  or 250 x3 , where x is any digit ::: Age ::: age ::: C0001779 ::: orga ::: known;diabetes mellitus, insulin-dependent ::: C0205309;C0011854 ::: qlco;dsyn ::: study subject ::: C0681850 ::: grup
phv00158820.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: DECADE_BIRTH ::: Decade of birth ::: encoded value ::: NONE ::: 1 ::: 9 ::: decade of birth ::: NULL ::: NULL ::: NULL ::: NULL ::: birth ::: C0005615 ::: orgf ::: study subject ::: C0681850 ::: grup
phv00158833.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Age_last_known_type2_diabetes_diagnosis_code ::: Age when last known type 2 diabetes diagnosis code was given (ICD-9 codes 250.00, 250.02, 250.20, 250.22, 250.30, 250.32, 250.40, 250.42, 250.50, 250.52, 250.60, 250.62, 250.70, 250.72, 250.80, 250.82, 250.90, 250.92) ::: integer, encoded value ::: Years ::: 18 ::: 90 ::: age when last known type 2 diabetes diagnosis code was given  icd 9 codes 250 00 , 250 02 , 250 20 , 250 22 , 250 30 , 250 32 , 250 40 , 250 42 , 250 50 , 250 52 , 250 60 , 250 62 , 250 70 , 250 72 , 250 80 , 250 82 , 250 90 , 250 92 ::: Age ::: age ::: C0001779 ::: orga ::: known;diabetes mellitus, non-insulin-dependent ::: C0205309;C0011860 ::: qlco;dsyn ::: study subject ::: C0681850 ::: grup
phv00158828.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Any_Abnormal_Glucose_Indicator ::: Were Any (random or fasting) Glucose Lab values Abnormal? ::: encoded value ::: NONE ::: NONE ::: NONE ::: were any  random or fasting  glucose lab values abnormal ::: NULL ::: NULL ::: NULL ::: NULL ::: randomization;random;fasting;glucose;values;plasma glucose measurement ::: C0034656;C0439605;C0015663;C0017725;C0042295;C0202042 ::: resa;qlco;fndg;bacs,carb,phsu;qlco;lbpr ::: study subject ::: C0681850 ::: grup
phv00158836.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Age_first_type2_diabetes_drug_prescribed ::: Age when first known type 2 diabetes drug (in the following classes: Sulfonylureas, Meglitinides, Biguanides, Thiazoldinediones, Alpha-glucosidase inhibitors, DPPIV inhibitor (sitagliptin), or the injectable exenatide) prescribed ::: integer, encoded value ::: Years ::: 12 ::: 90 ::: age when first known type 2 diabetes drug  in the following classes  sulfonylureas, meglitinides, biguanides, thiazoldinediones, alpha glucosidase inhibitors, dppiv inhibitor  sitagliptin , or the injectable exenatide  prescribed ::: Age ::: age ::: C0001779 ::: orga ::: known;diabetes mellitus, non-insulin-dependent;pharmaceutical preparations;pharmacologic substance;firstly;sulfonylurea compounds;meglitinide;meglitinides;biguanides;alpha-glucoside inhibitor;inhibitor;sitagliptin;exenatide;injection procedure;prescribed ::: C0205309;C0011860;C0013227;C1254351;C1279901;C0038766;C0065880;C1579432;C0005382;C1299007;C1999216;C1565750;C0167117;C1533685;C0278329 ::: qlco;dsyn;phsu;phsu;qlco;orch,phsu;orch,phsu;phsu;orch,phsu;phsu;qlco;orch,phsu;aapp,phsu;topp;hlca ::: study subject ::: C0681850 ::: grup
phv00158827.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Any_Abnormal_Glycosylated_Hemoglobin_Indicator ::: Were Any (glycosylated) Hemoglobin (A1c)  Lab values Abnormal ::: encoded value ::: NONE ::: NONE ::: NONE ::: were any  glycosylated  hemoglobin  a1 c  lab values abnormal ::: NULL ::: NULL ::: NULL ::: NULL ::: values ::: C0042295 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00158818.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: SEX ::: Gender ::: encoded value ::: NONE ::: NONE ::: NONE ::: gender ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: gender:type:point in time:^patient:nominal ::: C0804628 ::: clna ::: study subject ::: C0681850 ::: grup
phv00158822.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: ETHNICITY ::: Is Subject Hispanic/Latino? ::: encoded value ::: NONE ::: NONE ::: NONE ::: is subject hispanic latino ::: Ethnicity ::: hispanic americans;hispanics ::: C0019576;C0086409 ::: popg;popg :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00158823.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: SMOKING_STATUS ::: Last known Smoking status ::: string, encoded value ::: NONE ::: NONE ::: NONE ::: last known smoking status ::: NULL ::: NULL ::: NULL ::: NULL ::: last;known;smoking status ::: C1517741;C0205309;C1519386 ::: qlco;qlco;clna ::: study subject ::: C0681850 ::: grup
phv00158831.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Age_first_type2_diabetes_diagnosis_code ::: Age when first known type 2 diabetes diagnosis code was given (ICD-9 codes 250.00, 250.02, 250.20, 250.22, 250.30, 250.32, 250.40, 250.42, 250.50, 250.52, 250.60, 250.62, 250.70, 250.72, 250.80, 250.82, 250.90, 250.92) ::: integer, encoded value ::: Years ::: 11 ::: 90 ::: age when first known type 2 diabetes diagnosis code was given  icd 9 codes 250 00 , 250 02 , 250 20 , 250 22 , 250 30 , 250 32 , 250 40 , 250 42 , 250 50 , 250 52 , 250 60 , 250 62 , 250 70 , 250 72 , 250 80 , 250 82 , 250 90 , 250 92 ::: Age ::: age ::: C0001779 ::: orga ::: known;diabetes mellitus, non-insulin-dependent;firstly ::: C0205309;C0011860;C1279901 ::: qlco;dsyn;qlco ::: study subject ::: C0681850 ::: grup
phv00158837.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Age_last_known_type1_diabetes_drug_prescribed ::: Age when last known type 1 diabetes drug (insulin, Symlin, or any insulin supply) prescribed ::: integer, encoded value ::: Years ::: 14 ::: 90 ::: age when last known type 1 diabetes drug  insulin, symlin, or any insulin supply  prescribed ::: Age ::: age ::: C0001779 ::: orga ::: known;diabetes mellitus, insulin-dependent;pharmaceutical preparations;insulin;recombinant insulin;pharmacologic substance;symlin;prescribed ::: C0205309;C0011854;C0013227;C0021641;C1533581;C1254351;C1174780;C0278329 ::: qlco;dsyn;phsu;aapp,horm,phsu;aapp,horm,phsu;phsu;aapp,horm,phsu;hlca ::: study subject ::: C0681850 ::: grup
phv00158839.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Number_in_person_clinician_encounters ::: Number of in-person encounters the patient has had with a clinician as recorded in the EMR, as evidenced by problem or medication list or history entries/updates, or other evidence specific to each site's EMR ::: integer, encoded value ::: NONE ::: 1 ::: 405 ::: number of inperson encounters the patient has had with a clinician as recorded in the emr, as evidenced by problem or medication list or history entries updates, or other evidence specific to each site s emr ::: NULL ::: NULL ::: NULL ::: NULL ::: query quantity unit - records;problem;medical history;history of previous events;other;specific qualifier value ::: C1553414;C0033213;C0262926;C2004062;C0205394;C0205369 ::: qlco;fndg;fndg;fndg;qlco;qlco ::: patients ::: C0030705 ::: podg
phv00158824.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: CASE_CONTROL ::: T2DM Case or Control ::: encoded value ::: NONE ::: NONE ::: NONE ::: t2 dm case or control ::: NULL ::: NULL ::: NULL ::: NULL ::: control aspects ::: C0243148 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00158819.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: YEAR_BIRTH ::: Year of birth ::: integer, encoded value ::: NONE ::: 1912 ::: 1990 ::: year of birth ::: NULL ::: NULL ::: NULL ::: NULL ::: birth ::: C0005615 ::: orgf ::: study subject ::: C0681850 ::: grup
phv00158816.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: SUBJID ::: Deidentified Subject's ID ::: integer ::: NONE ::: NONE ::: NONE ::: deidentified subject s id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00158821.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: RACE ::: Subject's race ::: encoded value ::: NONE ::: NONE ::: NONE ::: subject s race ::: Race ::: racial group ::: C0034510 ::: popg :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00158840.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: HYPERTENSION ::: Hypertension status ::: integer, encoded value ::: NONE ::: NONE ::: NONE ::: hypertension status ::: NULL ::: NULL ::: NULL ::: NULL ::: hypertensive disease;status;hypertension adverse event ::: C0020538;C0449438;C1963138 ::: dsyn;qlco;fndg ::: study subject ::: C0681850 ::: grup
phv00158841.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Body_Mass_Index_average ::: Average Body Mass Index of participant, see comments for how average calculated ::: Decimal, encoded value ::: kg/m2 ::: 15 ::: 100 ::: average body mass index of participant, see comments for how average calculated ::: NULL ::: NULL ::: NULL ::: NULL ::: body mass index procedure;body mass index;vision;calculated (procedure) ::: C0005893;C1305855;C0042789;C1443182 ::: diap;clna;orgf;lbpr ::: participant ::: C0679646 ::: popg
phv00158829.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Any_diabetes_diagnosis_code_indicator ::: Were any diabetes diagnosis codes given (ICD-9 codes 250.xx, where x is any digit)? ::: encoded value ::: NONE ::: NONE ::: NONE ::: were any diabetes diagnosis codes given  icd 9 codes 250  xx, where x is any digit ::: NULL ::: NULL ::: NULL ::: NULL ::: diabetes;diagnosis;diagnosis aspect;diagnosis study;diabetes mellitus ::: C0011847;C0011900;C1704338;C1704656;C0011849 ::: dsyn;fndg;qlco;resa;dsyn ::: study subject ::: C0681850 ::: grup
phv00158830.v1 ::: phs000237.v1.p1 ::: pht002162.v1 ::: NU_VU_T2D_Subject_Phenotypes ::: Age_first_type1_diabetes_diagnosis_code ::: Age when first known type 1 diabetes diagnosis code was given (ICD-9 codes 250.x1 or 250.x3, where x is any digit) ::: integer, encoded value ::: Years ::: 10 ::: 90 ::: age when first known type 1 diabetes diagnosis code was given  icd 9 codes 250 x1  or 250 x3 , where x is any digit ::: Age ::: age ::: C0001779 ::: orga ::: known;diabetes mellitus, insulin-dependent;firstly ::: C0205309;C0011854;C1279901 ::: qlco;dsyn;qlco ::: study subject ::: C0681850 ::: grup
phv00158808.v1 ::: phs000237.v1.p1 ::: pht002160.v1 ::: NU_VU_T2D_Pedigree ::: SEX ::: Gender of participant ::: encoded value ::: NONE ::: NONE ::: NONE ::: gender of participant ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: gender:type:point in time:^patient:nominal ::: C0804628 ::: clna ::: participant ::: C0679646 ::: popg
phv00158810.v1 ::: phs000237.v1.p1 ::: pht002160.v1 ::: NU_VU_T2D_Pedigree ::: FATHER ::: Deidentified ID of Subject's Father ::: integer ::: NONE ::: NONE ::: NONE ::: deidentified id of subject s father ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: father (person) ::: C0015671 ::: famg
phv00158806.v1 ::: phs000237.v1.p1 ::: pht002160.v1 ::: NU_VU_T2D_Pedigree ::: FAMID ::: ID of family of related subjects ::: integer ::: NONE ::: NONE ::: NONE ::: id of family of related subjects ::: NULL ::: NULL ::: NULL ::: NULL ::: relationships;related personal status ::: C0439849;C0445223 ::: qlco;fndg ::: family ::: C0015576 ::: famg
phv00158807.v1 ::: phs000237.v1.p1 ::: pht002160.v1 ::: NU_VU_T2D_Pedigree ::: SUBJID ::: Deidentified Subject's ID ::: integer ::: NONE ::: NONE ::: NONE ::: deidentified subject s id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00158809.v1 ::: phs000237.v1.p1 ::: pht002160.v1 ::: NU_VU_T2D_Pedigree ::: MOTHER ::: Deidentified ID of Subject's Mother ::: integer ::: NONE ::: NONE ::: NONE ::: deidentified id of subject s mother ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: mother (person) ::: C0026591 ::: famg
phv00158811.v1 ::: phs000237.v1.p1 ::: pht002160.v1 ::: NU_VU_T2D_Pedigree ::: Ped_note ::: Pedigree Note ::: string ::: NONE ::: NONE ::: NONE ::: pedigree note ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00158812.v1 ::: phs000237.v1.p1 ::: pht002161.v1 ::: NU_VU_T2D_Sample ::: SUBJID ::: Subject ID ::: integer ::: NONE ::: NONE ::: NONE ::: subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00158815.v1 ::: phs000237.v1.p1 ::: pht002161.v1 ::: NU_VU_T2D_Sample ::: SOURCE_SAMPID ::: Sample ID used in the Source Repository ::: integer ::: NONE ::: NONE ::: NONE ::: sample id used in the source repository ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;source ::: C1273517;C0449416 ::: fndg;fndg ::: study subject ::: C0681850 ::: grup
phv00158814.v1 ::: phs000237.v1.p1 ::: pht002161.v1 ::: NU_VU_T2D_Sample ::: SAMP_SOURCE ::: Source repository where samples originate ::: string ::: NONE ::: NONE ::: NONE ::: source repository where samples originate ::: NULL ::: NULL ::: NULL ::: NULL ::: source ::: C0449416 ::: fndg ::: study subject ::: C0681850 ::: grup
phv00158813.v1 ::: phs000237.v1.p1 ::: pht002161.v1 ::: NU_VU_T2D_Sample ::: SAMPID ::: Sample ID ::: integer ::: NONE ::: NONE ::: NONE ::: sample id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00159406.v1 ::: phs000336.v1.p1 ::: pht002220.v1 ::: CGEMS_Lung_Cancer_Subject_Phenotypes ::: PLCO_EV5 ::: Principal components for population stratification ::: decimal ::: NONE ::: NONE ::: NONE ::: principal components for population stratification ::: NULL ::: NULL ::: NULL ::: NULL ::: stratification ::: C1514983 ::: resa ::: study subject ::: C0681850 ::: grup
phv00159404.v1 ::: phs000336.v1.p1 ::: pht002220.v1 ::: CGEMS_Lung_Cancer_Subject_Phenotypes ::: EAGLE_EV2 ::: Principal components for population stratification ::: decimal ::: NONE ::: NONE ::: NONE ::: principal components for population stratification ::: NULL ::: NULL ::: NULL ::: NULL ::: stratification ::: C1514983 ::: resa ::: study subject ::: C0681850 ::: grup
phv00159403.v1 ::: phs000336.v1.p1 ::: pht002220.v1 ::: CGEMS_Lung_Cancer_Subject_Phenotypes ::: AGE ::: Age-at-diagnosis/interview for case-control study and baseline age for cohort studies in 5 year interval ::: string ::: Years old ::: NONE ::: NONE ::: age at diagnosis interview for case control study and baseline age for cohort studies in 5 year interval ::: Age ::: age ::: C0001779 ::: orga ::: diagnosis;diagnosis aspect;diagnosis study;case-control studies ::: C0011900;C1704338;C1704656;C0007328 ::: fndg;qlco;resa;resa ::: study subject ::: C0681850 ::: grup
phv00159402.v1 ::: phs000336.v1.p1 ::: pht002220.v1 ::: CGEMS_Lung_Cancer_Subject_Phenotypes ::: GENDER ::: Gender of participant [FEMALE, MALE] ::: string ::: NONE ::: NONE ::: NONE ::: gender of participant  female, male ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: gender:type:point in time:^patient:nominal;female;female, self-report;female phenotype;male gender;male gender, self report;male phenotype ::: C0804628;C0015780;C1705497;C1705498;C0024554;C1706180;C1706428 ::: clna;fndg;qlco;qlco;fndg;qlco;qlco ::: participant ::: C0679646 ::: popg
phv00159407.v1 ::: phs000336.v1.p1 ::: pht002220.v1 ::: CGEMS_Lung_Cancer_Subject_Phenotypes ::: ATBC_EV2 ::: Principal components for population stratification ::: decimal ::: NONE ::: NONE ::: NONE ::: principal components for population stratification ::: NULL ::: NULL ::: NULL ::: NULL ::: stratification ::: C1514983 ::: resa ::: study subject ::: C0681850 ::: grup
phv00159399.v1 ::: phs000336.v1.p1 ::: pht002220.v1 ::: CGEMS_Lung_Cancer_Subject_Phenotypes ::: SUBJID ::: De-identified subject ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00159401.v1 ::: phs000336.v1.p1 ::: pht002220.v1 ::: CGEMS_Lung_Cancer_Subject_Phenotypes ::: CASECONTROL ::: Case or control? [CASE, CONTROL] ::: string ::: NONE ::: NONE ::: NONE ::: case or control   case, control ::: NULL ::: NULL ::: NULL ::: NULL ::: control aspects ::: C0243148 ::: qlco ::: study subject ::: C0681850 ::: grup
phv00159400.v1 ::: phs000336.v1.p1 ::: pht002220.v1 ::: CGEMS_Lung_Cancer_Subject_Phenotypes ::: STUDY ::: Name of the study ::: string ::: NONE ::: NONE ::: NONE ::: name of the study ::: NULL ::: NULL ::: NULL ::: NULL ::: clinical trials;study ::: C0008976;C2603343 ::: resa;resa ::: study subject ::: C0681850 ::: grup
phv00159405.v1 ::: phs000336.v1.p1 ::: pht002220.v1 ::: CGEMS_Lung_Cancer_Subject_Phenotypes ::: PLCO_EV4 ::: Principal components for population stratification ::: decimal ::: NONE ::: NONE ::: NONE ::: principal components for population stratification ::: NULL ::: NULL ::: NULL ::: NULL ::: stratification ::: C1514983 ::: resa ::: study subject ::: C0681850 ::: grup
phv00159396.v1 ::: phs000336.v1.p1 ::: pht002218.v1 ::: CGEMS_Lung_Cancer_Subject ::: Affection Status ::: Case control status of the subject [CASE, CONTROL] ::: string ::: NONE ::: NONE ::: NONE ::: case control status of the subject  case, control ::: NULL ::: NULL ::: NULL ::: NULL ::: case control;status;control aspects ::: C0872128;C0449438;C0243148 ::: hlca;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00159395.v1 ::: phs000336.v1.p1 ::: pht002218.v1 ::: CGEMS_Lung_Cancer_Subject ::: CONSENT ::: Consent group as determined by DAC ::: encoded value ::: NONE ::: NONE ::: NONE ::: consent group as determined by dac ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00159394.v1 ::: phs000336.v1.p1 ::: pht002218.v1 ::: CGEMS_Lung_Cancer_Subject ::: SUBJID ::: De-identified subject ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00159398.v1 ::: phs000336.v1.p1 ::: pht002219.v1 ::: CGEMS_Lung_Cancer_Sample ::: SAMPID ::: De-identified sample ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified sample id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00159397.v1 ::: phs000336.v1.p1 ::: pht002219.v1 ::: CGEMS_Lung_Cancer_Sample ::: SUBJID ::: De-identified subject ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00174252.v1 ::: phs000538.v1.p1 ::: pht003040.v1 ::: Mendelian_Familial_Hyperlipidemia_Sample ::: SAMPID ::: Sample ID ::: string ::: NONE ::: NONE ::: NONE ::: sample id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00174251.v1 ::: phs000538.v1.p1 ::: pht003040.v1 ::: Mendelian_Familial_Hyperlipidemia_Sample ::: SUBJID ::: Subject ID ::: string ::: NONE ::: NONE ::: NONE ::: subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00174253.v1 ::: phs000538.v1.p1 ::: pht003040.v1 ::: Mendelian_Familial_Hyperlipidemia_Sample ::: SAMPLE_USE ::: Use of Subject's sample ::: encoded value ::: NONE ::: NONE ::: NONE ::: use of subject s sample ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00174249.v1 ::: phs000538.v1.p1 ::: pht003039.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject ::: SOURCE_SUBJID ::: Subject ID used in the Source Repository ::: string ::: NONE ::: NONE ::: NONE ::: subject id used in the source repository ::: NULL ::: NULL ::: NULL ::: NULL ::: used by;source ::: C1273517;C0449416 ::: fndg;fndg ::: study subject ::: C0681850 ::: grup
phv00174250.v1 ::: phs000538.v1.p1 ::: pht003039.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject ::: AFFECTION_STATUS ::: Case control status of the subject ::: encoded value ::: NONE ::: NONE ::: NONE ::: case control status of the subject ::: NULL ::: NULL ::: NULL ::: NULL ::: case control;status ::: C0872128;C0449438 ::: hlca;qlco ::: study subject ::: C0681850 ::: grup
phv00174246.v1 ::: phs000538.v1.p1 ::: pht003039.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject ::: SUBJID ::: Subject ID ::: string ::: NONE ::: NONE ::: NONE ::: subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00174247.v1 ::: phs000538.v1.p1 ::: pht003039.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject ::: CONSENT ::: Consent group as determined by DAC ::: encoded value ::: NONE ::: NONE ::: NONE ::: consent group as determined by dac ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00174248.v1 ::: phs000538.v1.p1 ::: pht003039.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject ::: SUBJ_SOURCE ::: Source repository where subjects originate ::: string ::: NONE ::: NONE ::: NONE ::: source repository where subjects originate ::: NULL ::: NULL ::: NULL ::: NULL ::: source ::: C0449416 ::: fndg ::: study subject ::: C0681850 ::: grup
phv00174259.v1 ::: phs000538.v1.p1 ::: pht003042.v1 ::: Mendelian_Familial_Hyperlipidemia_Sample_Attributes ::: SAMPID ::: De-identified Sample ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified sample id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00174260.v1 ::: phs000538.v1.p1 ::: pht003042.v1 ::: Mendelian_Familial_Hyperlipidemia_Sample_Attributes ::: BODY_SITE ::: Body site where sample was collected ::: string ::: NONE ::: NONE ::: NONE ::: body site where sample was collected ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00174261.v1 ::: phs000538.v1.p1 ::: pht003042.v1 ::: Mendelian_Familial_Hyperlipidemia_Sample_Attributes ::: HISTOLOGICAL_TYPE ::: Cell or tissue type of sample ::: string ::: NONE ::: NONE ::: NONE ::: cell or tissue type of sample ::: NULL ::: NULL ::: NULL ::: NULL ::: histocompatibility testing ::: C0019633 ::: lbpr ::: study subject ::: C0681850 ::: grup
phv00174258.v1 ::: phs000538.v1.p1 ::: pht003041.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject_Phenotypes ::: AGE ::: Age in 2012 ::: string ::: Years ::: NONE ::: NONE ::: age in 2012 ::: Age ::: age ::: C0001779 ::: orga :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00174257.v1 ::: phs000538.v1.p1 ::: pht003041.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject_Phenotypes ::: AFFECTION_STATUS ::: Case - control status of the subject ::: encoded value ::: NONE ::: NONE ::: NONE ::: case control status of the subject ::: NULL ::: NULL ::: NULL ::: NULL ::: case control;status ::: C0872128;C0449438 ::: hlca;qlco ::: study subject ::: C0681850 ::: grup
phv00174256.v1 ::: phs000538.v1.p1 ::: pht003041.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject_Phenotypes ::: RACE ::: Race of participant ::: string ::: NONE ::: NONE ::: NONE ::: race of participant ::: Race ::: racial group ::: C0034510 ::: popg :::  :::  :::  ::: participant ::: C0679646 ::: popg
phv00174255.v1 ::: phs000538.v1.p1 ::: pht003041.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject_Phenotypes ::: SEX ::: Sex of participant ::: encoded value ::: NONE ::: NONE ::: NONE ::: gender of participant ::: Gender ::: gender ::: C0079399 ::: orga;orga ::: gender:type:point in time:^patient:nominal ::: C0804628 ::: clna ::: participant ::: C0679646 ::: popg
phv00174254.v1 ::: phs000538.v1.p1 ::: pht003041.v1 ::: Mendelian_Familial_Hyperlipidemia_Subject_Phenotypes ::: SUBJID ::: De-identified Subject ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00173337.v1 ::: phs000487.v1.p1 ::: pht002925.v1 ::: Prostate_Cancer_Risk_Subject_Phenotypes ::: CaseControl ::: Flag that indicates Case and Control status ::: string, categorical ::: NONE ::: NONE ::: NONE ::: flag that indicates case and control status ::: NULL ::: NULL ::: NULL ::: NULL ::: indicated;status;control aspects ::: C1444656;C0449438;C0243148 ::: fndg;qlco;qlco ::: study subject ::: C0681850 ::: grup
phv00173342.v1 ::: phs000487.v1.p1 ::: pht002925.v1 ::: Prostate_Cancer_Risk_Subject_Phenotypes ::: Aggressive.Phenotype.D'AmicoCriteria ::: Significance of the disease based upon D'Amico criteria ::: string, categorical ::: NONE ::: NONE ::: NONE ::: significance of the disease based upon d amico criteria ::: NULL ::: NULL ::: NULL ::: NULL ::: disease ::: C0012634 ::: dsyn ::: study subject ::: C0681850 ::: grup
phv00173341.v1 ::: phs000487.v1.p1 ::: pht002925.v1 ::: Prostate_Cancer_Risk_Subject_Phenotypes ::: Gleason.Score ::: Gleason Score ::: integer ::: NONE ::: NONE ::: NONE ::: gleason score ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00173336.v1 ::: phs000487.v1.p1 ::: pht002925.v1 ::: Prostate_Cancer_Risk_Subject_Phenotypes ::: SUBJID ::: De-identified subject ID ::: string ::: NONE ::: NONE ::: NONE ::: deidentified subject id ::: NULL ::: NULL ::: NULL ::: NULL :::  :::  :::  ::: study subject ::: C0681850 ::: grup
phv00173340.v1 ::: phs000487.v1.p1 ::: pht002925.v1 ::: Prostate_Cancer_Risk_Subject_Phenotypes ::: PSA.categorical.ng.ml ::: Level of prostate specific antigen (PSA) ::: string, categorical ::: ng/ml ::: NONE ::: NONE ::: level of prostate specific antigen  psa ::: NULL ::: NULL ::: NULL ::: NULL ::: levels (qualifier value);level;prostate specific antigen measurement ::: C0441889;C2946261;C0201544 ::: qlco;phsu;lbpr ::: study subject ::: C0681850 ::: grup
